23andMe Amends 10-K for Executive Equity Compensation Clarity
| Field | Detail |
|---|---|
| Company | 23andme Holding Co. |
| Form Type | 10-K/A |
| Filed Date | Jul 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K/A, Executive Compensation, Equity Awards, SEC Filing, Corporate Governance, Compliance, Genomics
TL;DR
**23andMe's 10-K/A is a necessary but unexciting compliance update, offering no new operational insights but crucial transparency on executive pay.**
AI Summary
23andMe Holding Co. filed a 10-K/A on July 25, 2025, for the fiscal year ended March 31, 2025, primarily to amend executive compensation disclosures. While specific revenue and net income figures are not detailed in the provided excerpt, the amendment focuses on equity awards for key personnel, including Anne Wojcicki and Joseph Selsavage, for the periods spanning April 1, 2021, through March 31, 2025. The filing details the year-end fair value of equity awards granted, outstanding, and unvested for both 'PEO' (Principal Executive Officer) and 'Non-PEO NEO' (Named Executive Officers) categories. It also addresses changes in fair value of outstanding and unvested equity awards granted in prior years, and the fair value as of vesting dates for awards granted and vested within the covered fiscal year. This amendment ensures compliance with SEC regulations regarding executive compensation transparency, which is crucial for investor understanding of management incentives and potential dilution.
Why It Matters
This 10-K/A filing is critical for investors as it provides a clearer picture of how 23andMe compensates its top executives, including Anne Wojcicki and Joseph Selsavage, through equity awards. Understanding these compensation structures helps investors assess management's alignment with shareholder interests and potential future dilution from stock-based compensation. For employees, it sets a precedent for executive incentives within the company. In the competitive genomics and pharmaceutical preparations sector, transparent compensation practices can influence investor confidence and market valuation, especially as 23andMe competes with established players and emerging biotech firms.
Risk Assessment
Risk Level: low — The risk level is low because this 10-K/A is an amendment primarily for executive compensation disclosures, not a restatement of financial results or a disclosure of new material adverse events. It corrects or clarifies previously filed information regarding equity awards for executives like Anne Wojcicki and Joseph Selsavage, which is a standard regulatory compliance activity and does not indicate new operational or financial risks.
Analyst Insight
Investors should review the detailed equity compensation figures for Anne Wojcicki and Joseph Selsavage to understand the full scope of executive incentives and potential future share dilution. This information can be factored into long-term valuation models, but no immediate trading action is warranted based solely on this compliance filing.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Anne Wojcicki | Principal Executive Officer (PEO) | |
| Joseph Selsavage | Non-PEO Named Executive Officer (NEO) |
Key Numbers
- 2025-03-31 — Fiscal Year End (The period of report for the 10-K/A filing.)
- 2025-07-25 — Filed As Of Date (The date the 10-K/A was filed with the SEC.)
- 001-39587 — SEC File Number (The SEC file number for 23andMe Holding Co.)
Key Players & Entities
- 23andMe Holding Co. (company) — Filer of the 10-K/A
- Anne Wojcicki (person) — Principal Executive Officer (PEO) whose equity awards are detailed
- Joseph Selsavage (person) — Named Executive Officer (NEO) whose equity awards are detailed
- SEC (regulator) — Regulator requiring the 10-K/A filing
- 0001804591 (regulator) — Central Index Key (CIK) for 23andMe Holding Co.
- 870 MARKET STREET, ROOM 415, SAN FRANCISCO, CA 94102 (company) — Business address of 23andMe Holding Co.
- VG Acquisition Corp. (company) — Former name of 23andMe Holding Co.
FAQ
What is the primary purpose of 23andMe's 10-K/A filing?
The primary purpose of 23andMe's 10-K/A filing on July 25, 2025, is to amend and clarify executive compensation disclosures, specifically regarding equity awards for the fiscal year ended March 31, 2025, and prior periods.
Which executives are mentioned in 23andMe's 10-K/A regarding equity awards?
The 10-K/A mentions Anne Wojcicki, identified as the Principal Executive Officer (PEO), and Joseph Selsavage, as a Named Executive Officer (NEO), in relation to their equity awards for the periods between April 1, 2021, and March 31, 2025.
What financial periods are covered by the equity award disclosures in 23andMe's 10-K/A?
The equity award disclosures in 23andMe's 10-K/A cover multiple financial periods, specifically from April 1, 2021, to March 31, 2025, detailing awards granted, outstanding, and vested within these fiscal years.
Does 23andMe's 10-K/A indicate a restatement of financial results?
No, 23andMe's 10-K/A does not indicate a restatement of financial results. It is an amendment focused solely on executive compensation disclosures, not on core financial statements like revenue or net income.
How does this 10-K/A impact investors in 23andMe?
This 10-K/A provides investors with greater transparency into 23andMe's executive compensation practices, particularly concerning equity awards. This information helps investors assess management incentives and potential future share dilution, which can influence long-term investment decisions.
What is the significance of the 'PEO' and 'Non-PEO NEO' categories in 23andMe's filing?
The 'PEO' (Principal Executive Officer) and 'Non-PEO NEO' (Named Executive Officers) categories are standard SEC classifications used to differentiate and detail compensation for the highest-ranking executive and other key executives, respectively, ensuring comprehensive disclosure.
What was 23andMe Holding Co.'s former name?
23andMe Holding Co. had several former names, including VG Acquisition Corp., Virgin Group Acquisition Corp., and Bleecker Street Acquisition Corp., with the most recent name change from VG Acquisition Corp. occurring on September 15, 2020.
Where is 23andMe Holding Co.'s business address?
23andMe Holding Co.'s business address is 870 Market Street, Room 415, San Francisco, CA 94102.
What is the Standard Industrial Classification (SIC) for 23andMe Holding Co.?
The Standard Industrial Classification (SIC) for 23andMe Holding Co. is Pharmaceutical Preparations [2834], indicating its primary business sector.
What type of information is typically found in a 10-K/A filing?
A 10-K/A filing is an amendment to an annual report (10-K) and typically contains corrections or updates to previously filed information, often related to executive compensation, financial disclosures, or other regulatory compliance matters, without necessarily changing the core financial results.
Industry Context
23andMe operates in the direct-to-consumer genetic testing and personalized health services sector, which is characterized by rapid technological advancements and increasing consumer interest in health and wellness data. The industry faces competition from other genetic testing companies, as well as traditional healthcare providers and digital health platforms.
Regulatory Implications
Amendments to executive compensation disclosures are driven by SEC regulations aimed at ensuring transparency for investors. Failure to accurately report compensation can lead to regulatory scrutiny and potential penalties.
What Investors Should Do
- Review the specific details of equity awards granted to Anne Wojcicki and Joseph Selsavage to understand their compensation structure and potential future dilution.
- Assess the impact of changes in the fair value of outstanding and unvested equity awards on the company's reported equity and potential future share count.
- Monitor future filings for any further amendments or disclosures related to executive compensation, as this is a key area of focus for the current filing.
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the financial information discussed in the 10-K/A.
- 2025-07-25: 10-K/A Filing Date — The date the amended filing was submitted to the SEC, indicating the latest point of disclosure for the company's financial and executive compensation information.
Glossary
- 10-K/A
- An amended annual report filed with the SEC to correct or supplement information previously filed in a Form 10-K. (This filing specifically amends executive compensation disclosures for 23andMe Holding Co.)
- PEO
- Principal Executive Officer, typically the Chief Executive Officer or equivalent. (Used to categorize executive compensation and equity awards for the top executive, Anne Wojcicki.)
- Non-PEO NEO
- Non-Principal Executive Officer Named Executive Officer. These are other top executives of the company whose compensation is disclosed. (Used to categorize executive compensation and equity awards for other key executives, such as Joseph Selsavage.)
- Fair Value of Equity Awards
- The estimated market value of stock options, restricted stock units, or other equity-based compensation. (Crucial for understanding the potential value and incentive associated with executive compensation packages.)
- Vesting Date
- The date on which an employee gains full ownership rights to their granted equity awards. (Indicates when executives can realize the value of their compensation, impacting their financial incentives.)
Year-Over-Year Comparison
This 10-K/A filing primarily focuses on amending executive compensation disclosures and does not appear to introduce significant changes to previously reported financial metrics like revenue or net income. The key update is the detailed breakdown and valuation of equity awards for PEO and Non-PEO NEOs, ensuring compliance with transparency requirements.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on July 25, 2025 by Anne Wojcicki regarding 23andMe Holding Co..